Novartis | NVS - Operating Expenses

Stock Price
151.02
Daily Change
2.33 1.57%
Monthly
9.50%
Yearly
44.32%
Q1 Forecast
145.07

Novartis reported $9.77B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
AstraZeneca USD 16.69B 5.74B Sep/2025
Bausch Health Companies USD 1.96B 109M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Canopy Growth CAD 80.99M 8.64M Sep/2025
Corcept Therapeutics USD 197.42M 29.66M Sep/2025
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
GlaxoSmithKline GBP 5.76B 203M Sep/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Merck USD 10.72B 1.28B Sep/2025
Novartis USD 9.86B 115M Sep/2025
Novartis USD 9.77B 401M Sep/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Prestige Brands USD 194.44M 16.67M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Sanofi EUR 10.71B 1.32B Dec/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025
Zoetis USD 5.4B 3.94B Sep/2025